Destiny Pharma Limited - In Liquidation Alternatives & Competitors
12 companies similar to Destiny Pharma Limited - In Liquidation — Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and...
Companies similar to Destiny Pharma Limited - In Liquidation
LIPUM AB
We have developed a biological drug SOL-116 for treatment of chronic inflammatory diseases
Umea, Sweden
Ansun Biopharma, Inc.
Discovering solutions for the world
San Diego, United States
Redx Pharma
Biotech company focusing on the discovery and development of novel targeted medicines to t...
United Kingdom
AUROBAC THERAPEUTICS
Tackling bacterial infections, antimicrobial resistance, and their consequences in acute c...
Lyon, France
Rival Readout
Competing with Destiny Pharma Limited - In Liquidation? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Avenzo Therapeutics
Developing the next generation of oncology therapies for patients
San Diego, United States
BridgeBio
We move at the speed of patient need.
Palo Alto, United States
Heartseed Inc.
Clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiom...
Japan
Septerna
Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.
South San Francisco, Unit...
Solid Biosciences
#TogetherWeAreSolid
Boston, United States
Pharmamel Drug Discovery
Development of new drugs for inflammatory diseases by putting melatonin at the service of...
Granada, Spain
Rubedo Life Sciences
Medicines to keep you biologically young by targeting the pathological cells that drive ch...
Sunnyvale, United States
About Destiny Pharma Limited - In Liquidation
Destiny Pharma Limited, a United Kingdom-based biotechnology firm founded in 1997, is now In Liquidation under the administration of Mark Smith and Stephen Cork as of 21 August 2024. Despite its innovative pipeline, the company has entered a critical phase of administration owing to its operational circumstances. The c...
development of anti-infectives, prevention of bacterial infections, clinical trials
hospitals, healthcare providers, medical professionals, biotechnology investors
Clinical Stage Biotechnology, Novel Medicines Development, Microbiome-based Biotherapeutics, C. Difficile Infection Prevention, Hospital Acquired Infection Control, Phase 3 Clinical Trials, Post-Surgical Infection Prevention, Staphylococcal Infection Prevention, MRSA Prevention, COVID-19 Prevention, Viral Respiratory Infection Prevention, Antimicrobial Resistance Solutions, Drug-resistant Bacteria Control, SPOR-COVTM Development, XF Drug Series Research
B2B, B2D
Licensing, Product Sales, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Destiny Pharma Limited - In Liquidation: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Destiny Pharma Limited - In Liquidation on 11 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
